Replies to post #1393 on Spotlight Innovation Inc. (fka STLT)

[Ecomike]

Yes it does!!!!! That is one more reason I am convinced this a real major biotech being formed here :-)

I already have about $10,000 in this one and plan to buy more, but waiting for more cash and some volume signs to make sure I don't miss some bargains under $1.50 should they ever show up. My average cost in STLT is about $3.50 to $4, and I bought 80% of the bottom 2 years ago at retail. Only cheaper shares issued were to the new CEO and 2 early convertible debt holders that bought at .25 and .75 that never sold.

Yes, he tried Barwawiki (the NY pump and dump clown that ruined Eagle oil) just long enough to figure out what a scam artist he is, and promptly fired him LOL. I put him in contact with Larry (Mantra) for advise on who not to use and why in the penny promo world...since he has tried and reviewed most of them and figured out what a waste of ... they are, since Larry has the experience there. The STLT CEO is more of a top tier venture capital guy with bio tech experience... I expect to see a move out of OTC to Nasdaq with in 2 years here.

[Ecomike]

News is out on STLT, they have signed a deal for the second part of Phase I drug trial for cancer for the top Cletic drug.

http://ih.advfn.com/p.php?pid=nmona&article=67801626&symbol=STLT

Item 1.01 Entry into a Material Definitive Agreement.



Effective July 14, 2015 Spotlight Innovation Inc.'s (the "Company") subsidiary Celtic Biotech Inc. ("Celtic") entered into a Clinical Study Management Agreement (the "Agreement") with ImmunoClin Ltd. ("ImmunoClin") whereby ImmunoClin is to conduct, on behalf of Celtic the second part of the study Open Label Phase I Clinical Trial of Crotoxin in Patients with Advanced Cancer using an Intravenous Route of Administration" (the "Study"). Pursuant to the Agreement the timing of the Study is expected to be 18 months, and Celtic has agreed to pay ImmunoClin an aggregate of Euro 525,330 ($576,865 USD based on current conversion rates) payable in installments (as defined in the Agreement) during the course of the Study.



The foregoing summary of Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, copy of which is filed as an Exhibit to this Current Report on Form 8-K and is incorporated herein by reference.